

Amendments to the Claims

Listing of the Claims:


This Listing of the Claims will replace all prior versions, and listings of the claims in the application.

1-124 (Canceled)

125. (Presently Amended): A hapten-carrier conjugate comprising
at least one hapten which is nicotine; or a nicotine derivative ~~or a salt thereof~~; and
~~at least one~~ a carrier which is a bacterial toxin and

wherein said hapten and said carrier are linked by a branch selected from the group of chemical moieties identified by CJ reference number consisting of:

CJ 0	Q
CJ 1	(CH ₂) _n Q
CJ 1.1	CO ₂ Q
CJ 1.2	COQ
CJ 1.3	OCH ₃
CJ 2	OCO(CH ₂) _n Q
CJ 2.1	OCOCH=Q
CJ 2.2	OCOCH(O)CH ₂
CJ 2.3	OCO(CH ₂) _n CH(O)CH ₂
CJ 3	CO(CH ₂) _n COQ
CJ 3.1	CO(CH ₂) _n CNQ
CJ 4	OCO(CH ₂) _n COQ
CJ 4.1	OCO(CH ₂) _n CNQ
CJ 5	CH ₂ OCO(CH ₂) _n COQ
CJ 5.1	CH ₂ OCO(CH ₂) _n CNQ
CJ 6	CONH(CH ₂) _n Q
CJ 7	Y(CH ₂) _n Q
CJ 7.1	CH ₂ Y(CH ₂) _n Q
CJ 8	OCOCH(OH)CH ₂ Q
CJ 8.1	OCO(CH ₂) _n CH(OH)CH ₂ Q
CJ 9	OCOC ₆ H ₅
CJ 10	



, wherein Q' is a modified

CJ 11 protein; and
 YCO(CH₂)_nCOQ

and wherein for each branch, n is independently an integer; Y is S, O, or NH; and Q is ~~selected from the group consisting of: a protein or peptide~~ a bacterial toxin carrier, ~~modified protein or peptide carrier~~, or another branch identified by its "CJ" reference number.

126. (Previously Presented): The hapten-carrier conjugate of claim 125, wherein n is from 3 to 20.

127. (Canceled)

128. (Previously Presented): The hapten-carrier conjugate of claim 125, wherein greater than one hapten is coupled to the carrier.

129. (Canceled)

130. (Canceled)

131. (Previously Presented): A pharmaceutical preparation comprising the hapten-carrier conjugate of claim 125, and a pharmaceutically acceptable excipient.

132. (Previously Presented): The pharmaceutical preparation of claim 131, further comprising an adjuvant.

133. (Previously Presented): The pharmaceutical preparation of claim 132, wherein the adjuvant is alum or RIBI adjuvant.

134. (Previously Presented): The pharmaceutical preparation of claim 133, wherein the adjuvant is alum.

135. (Previously Presented): The pharmaceutical preparation of claim 134, wherein the alum is aluminum hydroxide or aluminum phosphate.

136. (Previously Presented): The pharmaceutical preparation of claim 131, further comprising an auxiliary agent or supplementary active compound.

137. (Previously Presented): The pharmaceutical preparation of claim 131 which is suitable for parenteral administration to a human.

138. (Previously Presented): The pharmaceutical preparation of claim 131 which is suitable for oral, dermal or topical administration to a human.

139. (Canceled)

140. (Canceled)

141. (New) The hapten-carrier conjugate of claim 125, wherein the bacterial toxin is cholera toxin B, diphtheria toxin, tetanus toxoid, pertussis toxin, filamentous hemagglutinin, shiga toxin or pseudomonas exotoxin.

142. (New) A pharmaceutical preparation comprising the hapten carrier of claim 141, and a pharmaceutically acceptable carrier.